Jump Financial LLC Buys Shares of 37,710 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jump Financial LLC acquired a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 37,710 shares of the medical device company's stock, valued at approximately $1,358,000. Jump Financial LLC owned approximately 0.06% of Tandem Diabetes Care at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TNDM. AlphaQuest LLC lifted its holdings in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares during the last quarter. Assetmark Inc. increased its position in shares of Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares during the last quarter. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care in the 3rd quarter worth approximately $52,000. Finally, Smartleaf Asset Management LLC increased its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares during the last quarter.

Insider Activity at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The stock was bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on TNDM shares. The Goldman Sachs Group decreased their target price on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Wells Fargo & Company reiterated an "equal weight" rating and issued a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Royal Bank of Canada reduced their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Mizuho started coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $43.88.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM traded up $1.10 during midday trading on Thursday, reaching $17.67. The stock had a trading volume of 1,357,066 shares, compared to its average volume of 1,501,646. The stock has a market cap of $1.18 billion, a P/E ratio of -9.16 and a beta of 1.52. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The firm has a fifty day simple moving average of $20.78 and a two-hundred day simple moving average of $29.60.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.